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Blood-stage immunity to Plasmodium
chabaudi malaria following
chemoprophylaxis and sporozoite
immunization
Wiebke Nahrendorf1,2*†‡, Philip J Spence1†‡, Irene Tumwine1§, Prisca Le´vy1§,
William Jarra1, Robert W Sauerwein2, Jean Langhorne1*§
1Division of Parasitology, MRC National Institute for Medical Research, London,
United Kingdom; 2Department of Medical Microbiology, Radboud University Medical
Centre, Nijmegen, Netherlands
Abstract Protection against malaria in humans can be achieved by repeated exposure to infected
mosquito bites during prophylactic chloroquine treatment (chemoprophylaxis and sporozoites
(CPS)). We established a new mouse model of CPS immunization to investigate the stage and strain-
specificity of malaria immunity. Immunization with Plasmodium chabaudi by mosquito bite under
chloroquine cover does not generate pre-erythrocytic immunity, which is acquired only after
immunization with high sporozoite doses. Instead, CPS immunization by bite elicits long-lived
protection against blood-stage parasites. Blood-stage immunity is effective against a virulent,
genetically distinct strain of P. chabaudi. Importantly, if exposure to blood-stage parasitemia is
extended, blood-stage parasites induce cross-stage immunity targeting pre-erythrocytic stages. We
therefore show that CPS immunization can induce robust, long-lived heterologous blood-stage
immunity, in addition to protection against pre-erythrocytic parasites following high dose sporozoite
immunization. Cross-stage immunity elicited by blood-stage parasites may further enhance efficacy
of this immunization regimen.
DOI: 10.7554/eLife.05165.001
Introduction
Protective immunity against microorganisms is developed after repeated infection and recovery (Mutapi
et al., 2013). Vaccines are usually successful if they mimic these naturally acquired immune responses
(Fox, 1984; Mielcarek et al., 2006). While protection against viruses and bacteria can be induced by
vaccination with killed (inactivated) or live-attenuated pathogens (Delany et al., 2014), there is no
licensed vaccine for human parasitic diseases like malaria that pose a major global health burden.
The apicomplexan malaria parasite Plasmodium is transmitted by bites of female anopheline
mosquitoes. In the vertebrate host, sporozoites injected into the dermis migrate to the liver, where
they establish a clinically silent infection of hepatocytes. Merozoites are then released from the liver
and invade erythrocytes, leading to an exponential asexual replication cycle that is entirely responsible
for the clinical signs and symptoms associated with malaria. Immunity against severe disease can be
acquired following repeated infection, but sterile parasite clearance is rarely achieved (Goncalves
et al., 2014). Clinically immune adults in endemic areas still harbor parasites in their blood-stream
(Okell et al., 2009). These asymptomatic carriers also develop gametocytes, the form transmissible to
mosquitoes, thereby allowing the parasite to complete its life cycle.
To achieve malaria control and eventually eradication, transmission must be blocked (Kappe et al.,
2010). A vaccine that protects against pre-erythrocytic parasites, and thus outperforms naturally
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acquired immunity, would greatly facilitate this aim. Parasites that arrest during the liver stage, either
because of irradiation (Nussenzweig et al., 1967) or targeted gene deletion (Mueller et al., 2005),
can provide immunity against challenge infection. Indeed, immunization of human volunteers with
irradiated sporozoites can induce sterile protection in experimental settings (Clyde et al., 1973;
Seder et al., 2013). However, in the absence of acquired immunity to the blood-stage parasite
a pre-erythrocytic vaccine that is only partially effective, and therefore permits breakthrough
erythrocytic infections, will provide no protection against severe malaria (Bejon et al., 2011). The
inclusion of a blood-stage component together with an effective pre-erythrocytic vaccine is therefore
preferred to provide a multi-stage malaria vaccine that minimizes both transmission and disease
(Ellis et al., 2010; Goodman and Draper, 2010).
A recently described experimental malaria immunization protocol using chemoprophylaxis and
sporozoites (CPS) (Roestenberg et al., 2009) ensures exposure to pre-erythrocytic and blood-stage
parasites, and hence has the unique potential to induce protection against all Plasmodium life cycle
stages in the vertebrate host. Three immunizations with bites of 10–15 Plasmodium falciparum-
infected mosquitoes under chloroquine chemoprophylaxis are sufficient to elicit sterile protection
against homologous challenge in human volunteers (Roestenberg et al., 2009; Bijker et al., 2013,
2014). Although it is not possible to measure liver parasite burden in human volunteers directly, it
appears that immunity exclusively targets pre-erythrocytic parasite life cycle stages, as there is no
protection against direct blood challenge (Bijker et al., 2013). CPS immunization is thus substantially
more effective than immunization with irradiated sporozoites, which requires 1000 mosquito bites
eLife digest Malaria is a life-threatening infectious disease in humans that is caused by a single-
celled parasite called Plasmodium. The parasite is carried between people by mosquitos; when an
infected mosquito bites a human, the parasite is injected into the bloodstream with the mosquito’s
saliva. Plasmodium first infects liver cells but then re-enters the bloodstream, where it infects red
blood cells leading to symptoms of disease. If another mosquito bites the infected individual at this
so-called ‘blood-stage’, the parasite can be passed to this mosquito and the cycle of transmission
continues.
Currently there are no vaccines available that can effectively protect against malaria. Although an
experimental vaccine containing a weakened form of the parasite can protect against the liver-stage
parasites, it fails to prevent the parasite from multiplying in the red blood cells. Therefore, the
individuals remain susceptible to severe malaria.
Recently, researchers have developed a new strategy for immunization that provides exposure to
both liver-stage and blood-stage parasites. Human volunteers taking an anti-malarial drug were
deliberately exposed to mosquitos carrying the parasite on three separate occasions. Although the
volunteers were infected with the parasite, the anti-malarial drug killed the parasites inside the red
blood cells. After the end of the drug treatment, the volunteers were exposed to mosquitos carrying
the parasite and they were still protected from infection. These results are promising, but it is not
clear if the volunteers have acquired immunity to liver-stage or blood-stage parasites, or even both.
To answer this important question, Nahrendorf et al. developed a similar immunization strategy in
mice. Just like the human volunteers, the mice were treated with an anti-malarial drug and exposed
to mosquitos carrying Plasmodium on three separate occasions. Although the immunizations did not
protect the mice against early infection in the liver, they did provide long-term protection against
parasites multiplying in the red-blood cells.
The immunity generated by this immunization strategy also protected the mice against another
strain of Plasmodium, different to the one used in the immunizations. The experiments also show that
prolonged exposure to the blood-stage parasites can even lead to immunity against the liver-stage
parasites.
Nahrendorf et al.’s findings show that this immunization strategy can protect individuals against
both the liver-stage and blood-stage parasites. The next challenges are to find out how the immunity
generated by one stage of infection can protect against the other stages, and to discover which
molecules on the parasite the immune system targets.
DOI: 10.7554/eLife.05165.002
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(Clyde et al., 1973) or five intravenous (iv) injections of more than 100,000 sporozoites for sterile
protection (Seder et al., 2013). We therefore hypothesize that transient blood-stage parasitemia,
before abrogation by chloroquine, may contribute to immunity following CPS immunization.
In this study, we have investigated the stage- and strain-specificity of protection in a novel mouse
model of CPS immunization using Plasmodium chabaudi. P. chabaudi establishes a chronic, non-lethal
blood-stage infection, which has been used extensively to characterize the immune response to
blood-stage parasites in vivo (Stephens et al., 2012). A recently optimized protocol for P. chabaudi
mosquito transmission (Spence et al., 2012) allows us now to also study pre-erythrocytic stages of this
rodent parasite. Heterologous protection can readily be assessed since many genetically distinct
P. chabaudi isolates displaying a variety of virulence phenotypes are available (Mackinnon and Read,
1999; Otto et al., 2014). We immunized C57BL/6 mice three times with bites of P. chabaudi-infected
mosquitoes under oral chloroquine chemoprophylaxis similar to human clinical trials (Roestenberg
et al., 2009; Bijker et al., 2013, 2014). This approach is unique amongst all published animal models
of CPS immunization (Beaudoin et al., 1977; Golenser et al., 1977;Orjih et al., 1982; Belnoue et al.,
2004; Friesen and Matuschewski, 2011; Inoue et al., 2012; Nganou-Makamdop et al., 2012b; Doll
et al., 2014; Lewis et al., 2014; Peng et al., 2014), which have (without exception) used iv injection of
high numbers of Plasmodium berghei or Plasmodium yoelii sporozoites for immunization.
Furthermore, rather than evaluating effector mechanisms by challenging shortly after immunization
(Beaudoin et al., 1977; Belnoue et al., 2004; Friesen and Matuschewski, 2011), we performed the
challenge 100 days after the final immunization to test the generation and maintenance of long-term
immunological memory.
CPS immunization with P. chabaudi by mosquito bite does not generate pre-erythrocytic immunity,
which is acquired only after immunization with high doses of sporozoites. Instead, immunization by
bite elicits blood-stage immunity that is effective against the immunizing strain and also a more
virulent, genetically distinct P. chabaudi. Moreover, extended exposure to blood-stage parasitemia
elicits robust pre-erythrocytic immunity, comparable to protection afforded by high dose sporozoite
immunization. Exposure to blood-stage parasites thus elicits heterologous blood-stage immunity and
can contribute to the pre-erythrocytic efficacy of this immunization regimen. Therefore, these findings
add significantly to advances from previous CPS immunization mouse models by evaluating the
generation of immune memory after immunization with P. chabaudi by mosquito bite. This is relevant
for our understanding of acquired immunity in a malaria endemic setting, and can inform multi-stage
malaria vaccine development.
Results
We investigated the stage- and strain-specificity of protection in a novel mouse model of CPS
immunization (Figure 1). C57BL/6 mice were immunized three times at 2-week intervals with P.
chabaudi AS-infected mosquito bites. For certain experimental questions, it was necessary to deviate
from the natural route of infection and inject sporozoites iv to control the dose. Starting on the day of
infection, mice were then treated orally with 100 mg per kg chloroquine for 10 days following each
immunization. To assess the long-term efficacy of acquired immunity, mice were challenged
approximately 100 days after the last immunization. Protection against pre-erythrocytic or blood-
stage parasites was evaluated after mosquito bite or direct blood challenge.
CPS immunization leads to a transient blood-stage infection
Transient blood-stage parasitemia is a key feature of CPS immunization. We used quantitative
RealTime (qRT) PCR to measure erythrocytic parasite burden after each immunization with
P. chabaudi AS-infected mosquito bites under chloroquine cover. After the first immunization,
approximately 50,000 parasites per ml whole blood were detected within the first erythrocytic cycle
(Figure 2). The amount of blood-stage parasites within the first erythrocytic cycle varied extensively
(median 47,596, range 67–222,699), reflecting the stochastic inoculation of sporozoites during
mosquito bite (Beier et al., 1991; Ponnudurai et al., 1991; Medica and Sinnis, 2005). Thereafter,
chloroquine reduced parasitemia by 86–96% every 24 hr. After the fourth cycle, the majority of
erythrocytic parasites were cleared. Similarly, after the second and third immunization mice
experienced a substantial number of circulating blood-stage parasites for 48–72 hr. However,
although blood-stage parasites were detected in all but one mouse, parasitemia in the first
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erythrocytic cycle was reduced by 5- and 13-fold after the second and third immunizations,
respectively, when compared to infection controls (Figure 2). Consequently, one CPS immunization is
sufficient to reduce blood-stage parasite burden within the first erythrocytic cycle, which indicates
either pre-erythrocytic or blood-stage immunity.
Figure 1. Overview of experimental procedures. To quantify transient blood-stage exposure during chemoprophylaxis and sporozoite (CPS) immunization
female C57BL/6 were immunized three times at 2-week intervals with P. chabaudi AS-infected mosquito bites (typically 9.15 [median, range 6.9–13.6]
[Spence et al., 2012]). Following each immunization mice received 100 mg per kg chloroquine (CQ) per os daily for 10 days, starting from the day of
infection. A small blood sample was taken 48 hr after each mosquito transmission (before merozoite egress from the liver, P. chabaudi develops in the liver
for 52 hr [Stephens et al., 2012]; erythrocytic cycle 0), and then every 24 hr until erythrocytic replication cycle 4. Blood parasitemia was analyzed by
sensitive quantitative RealTime (qRT) PCR (Figure 2). Pre-erythrocytic immunity was evaluated in mice immunized three times with either P. chabaudi
AS-infected mosquito bites (Figure 3A) or by intravenous (iv) injection of defined numbers of P. chabaudi CB sporozoites (Figure 3B). P. chabaudi CB was
used since mosquitoes infected with this parasite harbor an increased number of sporozoites in their salivary glands (Spence et al., 2012), which made
injections of high numbers of sporozoites technically feasible. Mice were challenged 100 days after the last immunization by mosquitoes infected with the
respective homologous strain. Liver parasitemia was examined 42 hr after challenge by qRT PCR. Blood-stage immunity was assessed in mice immunized
with P. chabaudi AS-infected mosquito bites by qRT PCR and thin blood film following homologous challenge with either infected mosquito bites
(Figures 4A, 5C/D) or intraperitoneal (ip) injection of parasitized erythrocytes, which were either derived from a donor mouse infected by mosquito bite
(recently mosquito transmitted, Figure 4B) or after 26–32 serial blood-passages (Figure 4C). Heterologous protection was assessed using P. chabaudi
CB-infected mosquito bites (Figure 5A/B). To evaluate cross-stage protection mice received a first infection with P. chabaudi AS either by mosquito bite
or by ip injection of recently mosquito transmitted parasitized erythrocytes. The resulting blood-stage infection was eventually self-cured without
intervention. Mice were re-challenged 100 days after their first infection with P. chabaudi AS-infected mosquito bites and liver parasitemia was evaluated
by qRT PCR (Figure 6).
DOI: 10.7554/eLife.05165.003
Nahrendorf et al. eLife 2015;4:e05165. DOI: 10.7554/eLife.05165 4 of 17
Research article Immunology | Microbiology and infectious disease
Pre-erythrocytic immunity requires
high doses of sporozoites during
CPS immunization
In order to assess directly whether pre-
erythrocytic immunity was generated by this
CPS immunization protocol, liver parasite burden
was analyzed after mosquito bite challenge.
Surprisingly, there was no difference in the liver
parasite burden between mice given three CPS
immunizations with P. chabaudi AS-infected
mosquito bites and infection controls
(Figure 3A). Therefore, immunization by mos-
quito bite under chloroquine cover according to
this protocol failed to elicit pre-erythrocytic
immunity. This is in contrast to results from other
animal models of CPS immunization where pre-
erythrocytic immunity is induced after high
numbers of sporozoites are injected iv (Belnoue
et al., 2004; Friesen and Matuschewski, 2011;
Inoue et al., 2012; Nganou-Makamdop et al.,
2012b; Lewis et al., 2014; Peng et al., 2014). To
test if pre-erythrocytic immunity can be induced
after CPS immunization with large numbers of
sporozoites, we used P. chabaudi CB, since
mosquitoes infected with this parasite strain
harbor an increased number of sporozoites in
their salivary glands compared to P. chabaudi AS
(Spence et al., 2012), making these experiments
technically feasible. In agreement with previous
studies (Belnoue et al., 2004; Friesen and
Matuschewski, 2011; Inoue et al., 2012;
Nganou-Makamdop et al., 2012b; Lewis
et al., 2014; Peng et al., 2014), mice immunized
iv three times with 10,000 P. chabaudi CB
sporozoites under chloroquine cover did show
reduced liver parasite burden (up to 90%) after
mosquito bite challenge, compared to infection controls (Figure 3B). Conversely, mice immunized iv
three times with a low dose of 100 P. chabaudi CB sporozoites (representative of the estimated
number of P. chabaudi sporozoites that initiate infection via mosquito bite, Spence et al., 2012) do
not acquire pre-erythrocytic immunity (Figure 3B). It also appears that CPS immunization with 10,000
live sporozoites was more effective at inducing pre-erythrocytic immunity than immunization with
10,000 irradiated P. chabaudi CB sporozoites, which arrest during hepatic development (Suhrbier
et al., 1990) and do not establish a blood-stage infection (Figure 3B). This suggests that complete
liver-stage maturation and the increased blood-stage parasitemia that accompanies immunization
with 10,000 sporozoites (as compared to 100 sporozoites or mosquito bite) could contribute to
pre-erythrocytic protection.
CPS immunization by mosquito bite elicits blood-stage immunity
To test whether the transient blood-stage infection resulting from CPS immunization by mosquito bite
(Figure 2) is sufficient to induce protection against erythrocytic parasites, we challenged mice
approximately 100 days after the last immunization and measured blood-stage parasitemia (Figure 4).
Mice that were CPS immunized with P. chabaudi AS had similar numbers of parasitized erythrocytes as
compared to mock immunized controls within the first five erythrocytic cycles following mosquito bite
challenge (Figure 4A). However, from erythrocytic cycle 6 parasitemia was significantly reduced and
blood-stage parasites were cleared more rapidly in immunized mice. This was reflected in a 6-fold
Figure 2. Chloroquine permits transient blood-stage
parasitemia during each immunization. The number of
parasitized erythrocytes (pE) per ml of whole blood was
enumerated by quantitative RealTime PCR after each
CPS immunization (i1, i2, i3) with P. chabaudi AS-
infected mosquito bites under chloroquine (CQ) cover.
The number of pE (at the late trophozoite stage) was
quantified immediately before merozoite egress from
the liver, at 48 hr post mosquito transmission (erythro-
cytic cycle 0), and then every 24 hr until erythrocytic
replication cycle 4. Daily parasitemia of 10 CPS
immunized mice (each color represents an individual
mouse) are shown. Blood-stage parasites were detected
within the first erythrocytic cycle after every immuniza-
tion in all but one mouse after the final immunization.
Gray bars represent the mean parasitemia in the first
erythrocytic cycle of naive mice infected as controls for
mosquito transmission efficiency separate with each
immunization (n = 3–5). Significant differences in the
number of blood-stage parasites in the first erythrocytic
cycle between naive and CPS immunized mice are
indicated (Mann Whitney test, **p ≤ 0.01).
DOI: 10.7554/eLife.05165.004
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reduction of total area under the curve (AUC) (right inset, Figure 4A). Protection against erythrocytic
parasites was also evaluated by direct blood challenge, using blood-stage parasites obtained from
a donor mouse infected by mosquito bite. Similar to the results of mosquito bite challenge, blood-
stage parasitemia was significantly reduced (Figure 4B), but the infection was still chronic in some
mice (Figure 4—figure supplement 1). However, blood-stage protection was abrogated when CPS
immunized mice were challenged with serially blood passaged (SBP) P. chabaudi; blood-stage
parasites with increased virulence following multiple passages through naive mice (Spence et al.,
2013, Figure 4C). In this case, CPS immunization reduced blood-stage parasite burden only between
erythrocytic cycle 6 and 8, as compared to mock immunized controls. This was reflected in only
a 1.2-fold reduction in total AUC (right inset, Figure 4C). Therefore, CPS immunization by mosquito
bite elicits homologous blood-stage immunity, which is most effective in the context of mosquito
transmission.
CPS immunization elicits heterologous blood-stage immunity
CPS immunization has so far not been shown to induce protection against challenge with genetically
distinct strains of Plasmodium; a situation that would be encountered in human malaria-endemic
areas. The genetic diversity amongst strains of P. chabaudi (Mackinnon and Read, 1999; Otto et al.,
2014) allows us to investigate heterologous immunity in this model of CPS immunization. Mice that
were CPS immunized with P. chabaudi AS-infected mosquito bites had reduced peak parasitemia, and
blood-stage parasites were cleared faster, when compared to mock immunized mice after
homologous (P. chabaudi AS) and heterologous (P. chabaudi CB) mosquito bite challenge
(Figure 5A–D). A direct comparison between P. chabaudi AS and CB challenge revealed nonetheless
that homologous blood-stage immunity is more effective than heterologous immunity. In this
experiment, CPS immunization reduced total AUC by 25-fold following homologous challenge, as
Figure 3. Pre-erythrocytic immunity following CPS immunization requires high doses of sporozoites. Liver parasite
burden was determined 42 hr after mosquito bite challenge as copy number of P. chabaudi-specific 18S rRNA.
(A) Mice were CPS immunized three times (i1, i2, i3) with P. chabaudi AS-infected mosquito bites under chloroquine
(CQ) cover (CPS (Bite)) and challenged (C) 96–104 days after immunization by bites of P. chabaudi AS-infected
mosquitoes (pooled data from three independent experiments; naive infection controls (−) n = 25, CPS (Bite) n = 35).
(B) 100 or 10,000 untreated or irradiated (Irr.) P. chabaudi CB sporozoites (spz) were injected iv three times under
CQ cover. Mice were challenged 96 days after immunization by bites of P. chabaudi CB-infected mosquitoes (naive
infection controls (−) n = 12, all other groups n = 20). All data are displayed relative to the mean of corresponding
liver parasite burden of naı¨ve infection controls and presented as mean ± SEM, (A) Mann–Whitney test: no
significant difference between the groups; (B) Kruskal Wallis with Dunn’s multiple comparisons test *p ≤ 0.05,
***p ≤ 0.001.
DOI: 10.7554/eLife.05165.005
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Figure 4. CPS immunization elicits blood-stage immunity. Mice were CPS immunized three times (i1, i2, i3) using
chloroquine (CQ) and P. chabaudi AS-infected or uninfected mosquito bites (mock immunized). Approximately 100
days after the final CPS immunization, mice were challenged (C) with P. chabaudi AS. Erythrocytic parasitemia was
evaluated daily by quantitative RealTime PCR (cycle 1–3, displayed as parasitized erythrocytes (pE) per ml whole
blood; left) and from cycle 3–14 by thin blood-film (expressed as % parasitized erythrocytes [parasitemia] 0.01%
parasitemia corresponds to 1,000,000 pE per ml; middle). The total area under the curve (AUC) was calculated
for each mouse between erythrocytic cycle 3 and 14 (right). (A) Mosquito bite challenge: parasitemia from 1st to 3rd
(n = 10) and between 3rd and 14th erythrocytic cycle (representative of three independent experiments, n = 12–19),
total AUC between cycle 3 and 14 (n = 19). (B) Direct blood challenge using 10,000 erythrocytic parasites obtained
from a donor mouse infected by mosquito bite; injected intraperitoneal (ip): parasitemia between 1st and 3rd (n = 10)
and 3rd and 14th erythrocytic cycle (representative of three independent experiments, n = 10), total AUC between
cycle 3 and 14 (n = 10). (C) Blood challenge using 10,000 serially blood passaged parasites; injected ip: parasitemia
from 1st to 3rd (n = 10) and between 3rd and 14th erythrocytic cycle (representative of two independent experiments,
Figure 4. continued on next page
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compared to 6-fold following heterologous challenge (Figure 5E). Nevertheless, CPS immunization
elicits blood-stage protection against a robust heterologous challenge with the genetically distinct,
and more virulent, CB strain of P. chabaudi.
Extended exposure to blood-stage parasites elicits robust
pre-erythrocytic immunity
Blood-stage parasites appear to be both the source and target of protection following CPS
immunization with P. chabaudi AS-infected mosquito bites. It was shown that immunization with
serially blood passaged P. yoelii parasites with prophylactic chloroquine treatment can elicit
pre-erythrocytic immunity (Belnoue et al., 2008). We wanted to assess whether blood-stage parasites
have the potential to induce pre-erythrocytic protection also in the context of mosquito transmission.
We therefore asked whether a fulminant blood-stage infection could elicit cross-stage immunity
against pre-erythrocytic parasites. We infected mice with P. chabaudi AS by mosquito bite or
intraperitoneal (ip) injection of recently mosquito transmitted blood-stage parasites. The two groups
of mice were not drug-treated, and therefore experienced a low-grade chronic, recrudescing blood-
stage infection for up to 90 days (Spence et al., 2013). After mosquito bite challenge, both groups of
mice demonstrated reduced liver parasite burden (up to 85%), compared to infection controls
(Figure 6). Cross-stage immunity is therefore a powerful mechanism for protection against pre-
erythrocytic parasites, which may be absent during CPS immunization with small sporozoite numbers
as the blood-stage infection is curtailed by the use of chloroquine.
Discussion
Timing, route of infection, and antigen dose play major roles in determining the initial priming of the
antimalarial immune response (Legorreta-Herrera et al., 2004; Elliott et al., 2005; Belnoue et al.,
2008; Guilbride et al., 2012; Nganou-Makamdop et al., 2012a). We incorporated many of these
aspects from human clinical trials (Roestenberg et al., 2009; Bijker et al., 2013, 2014) in a new
P. chabaudi mouse model of CPS immunization to investigate the stage- and strain-specificity of CPS-
induced protection against malaria. Our results highlight the complexity of immunity against the
different life cycle stages of the malaria parasite (Table 1). Pre-erythrocytic immunity appears to
depend on the number of immunizing sporozoites. In this study, we find no evidence of pre-
erythrocytic immunity after CPS immunization with P. chabaudi infected mosquito bites, which
inoculate an estimated maximum of 100 sporozoites per immunization (Spence et al., 2012, 2013).
Sterile pre-erythrocytic protection was however reported in human CPS immunization trials
(Roestenberg et al., 2009; Bijker et al., 2013, 2014). Anopheles stephensi mosquitoes
experimentally infected with P. falciparum 3D7 or NF54 habor 50–200 times more sporozoites in
their salivary glands (Bijker et al., 2013) compared to P. chabaudi AS (Spence et al., 2012). However,
only few sporozoites are injected into the skin during mosquito bite and this number is independent of
salivary gland sporozoites load (Beier et al., 1991; Ponnudurai et al., 1991; Medica and Sinnis,
2005). Since the number of sporozoites establishing a liver-stage infection can further be influenced
by inherent sporozoite infectivity (Khan and Vanderberg, 1991), our best estimate of immunizing
sporozoite dose is the number of infected erythrocytes observed directly after egress from the liver.
Assuming that 10,000 merozoites are released from one infected liver cell (White et al., 2014), we
estimate approximately 400 infected hepatocytes (95% CI 137–1250) in human volunteers (Bijker
et al., 2013) compared to 5 in P. chabaudi AS immunized mice (95% CI 1–31). Therefore, the number
of infected hepatocytes after CPS immunization by mosquito bite in the P. chabaudi mouse model is
approximately 100-fold lower than in CPS immunized humans. We show that this differences in
Figure 4. Continued
n = 8–10), total AUC between cycle 3 and 14 (n = 10). All data are presented as mean ± SEM, Mann–Whitney test per
time point *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
DOI: 10.7554/eLife.05165.006
The following figure supplement is available for figure 4:
Figure supplement 1. Chronic blood-stage infection in CPS immunized mice.
DOI: 10.7554/eLife.05165.007
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infected hepatocyte numbers by a factor of 100 can be significant for the development of pre-
erythrocytic immunity: three immunizations with 10,000 P. chabaudi sporozoites iv induce long-lasting
protection against mosquito bite challenge, while three immunizations with 100 P. chabaudi
sporozoites fail to do so. This is in general agreement with other rodent malaria studies using
P. berghei (Beaudoin et al., 1977; Golenser et al., 1977; Orjih et al., 1982; Friesen and
Matuschewski, 2011; Nganou-Makamdop et al., 2012b; Lewis et al., 2014) or P. yoelii (Belnoue
et al., 2004; Inoue et al., 2012; Doll et al., 2014; Peng et al., 2014), in which sterile pre-erythrocytic
immunity is observed after immunization with high sporozoite doses (typically 10,000–50,000
sporozoites per immunization), while a reduction in sporozoite dose or the number of immunizations
leads to breakthrough blood-stage infections upon challenge (Belnoue et al., 2004; Inoue et al.,
2012). Reduction of the number of P. falciparum-infected mosquitoes also reduces the frequency of
sterilely protected volunteers (Bijker et al., 2014), indicating that the number of sporozoites
establishing a liver-stage infection fails to surpass the protective threshold to elicit sterile
Figure 5. CPS immunization elicits heterologous blood-stage immunity. Mice were CPS immunized three times (i1,
i2, i3) under chloroquine (CQ) cover by P. chabaudi AS-infected mosquito bites or mock immunized with uninfected
mosquito bites, and challenged (C) 96–107 days later by mosquito bite. Erythrocytic parasitemia was evaluated daily
by quantitative RealTime PCR for blood-stage parasites (cycle 1–3, displayed as parasitized erythrocytes (pE) per ml
whole blood) and from cycle 3–20 by thin blood-film (expressed as % parasitized erythrocytes [parasitemia], 0.01%
parasitemia corresponds to 1,000,000 pE per ml). (A/B) Heterologous challenge with P. chabaudi CB infected
mosquitoes (A) Parasitemia between 1st and 3rd (n = 10) and (B) from 3rd to 20th erythrocytic cycle (n = 20).
(C/D) Homologous challenge with P. chabaudi AS-infected mosquitoes (C) Parasitemia between 1st and 3rd (n = 10)
and (D) from 3rd to 20th erythrocytic cycle (CPS immunized n = 20, mock immunized n = 19). (E) Total AUC comparing
mock and CPS immunized mice receiving heterologous or homologous mosquito bite challenge. Data are
presented as mean ± SEM, (A–D) Mann–Whitney test per time point (E) Kruskal Wallis with Dunn’s multiple
comparisons test *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
DOI: 10.7554/eLife.05165.008
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pre-erythrocytic immunity. This may also explain
why in malaria-endemic areas pre-erythrocytic
immunity is thought to be absent (Tran et al.,
2013). In addition to maximizing specific
responses against immunodominant antigens,
CPS immunization with high numbers of sporo-
zoites may broaden the immune repertoire by
including protective responses against subdomi-
nant antigens, which could enhance heterolo-
gous pre-erythrocytic protection (Trieu et al.,
2011). This may further be enhanced by the
longer liver-stage development of P. falciparum
(egress 6.8 days after mosquito bite, Roestenberg
et al., 2012) compared to P. chabaudi (egress
after 52 hr, Stephens et al., 2012). Longer liver
stage development may positively influence the
generation of pre-erythrocytic immunity by allow-
ing time for protective immune responses to
develop.
A key feature of CPS immunization is that it
permits exposure to all Plasmodium life cycle
stages in the vertebrate host, including parasit-
ized erythrocytes. It is well known that repeated
exposure to blood-stage parasites, for example,
in rodent models (Jarra and Brown, 1985;
Legorreta-Herrera et al., 2004; Elliott et al.,
2005), in humans exposed to ultra-low doses of
parasitized erythrocytes while receiving drug
treatment (Pombo et al., 2002), during malaria-
therapy of neurosyphilis patients (Collins and
Jeffery, 1999), and in people living in malaria-
endemic areas (Bull et al., 1998), induces blood-
stage immunity. Our results also clearly show that
during CPS immunization repeated transient
blood-stage infection (less than 0.01% para-
sitemia for 48–72 hr) elicits long-lasting blood-
stage immunity. Protection against challenge
infection was only apparent after multiple eryth-
rocytic replication cycles and patent blood-stage parasite densities, which could indicate that blood-
stage protection was not observed in CPS immunized human volunteers after direct blood-challenge
because drug treatment is required at low parasite densities as soon as patency is reached (typically
between the third and fourth erythrocytic cycle, Bijker et al., 2013). Blood-stage parasites are
however recognized in human volunteers, which was demonstrated by an earlier increase of IFNγ and
monokines induced by IFNγ (MIG) concentrations in CPS immunized volunteers compared to infection
controls after direct blood challenge (Bijker et al., 2013). It will be of value to investigate whether the
observed blood-stage protection in this mouse model is also detected in CPS immunized primates,
where a longer blood-stage infection than that allowed in human clinical trials is possible.
Despite the reduced peak parasitemia and faster clearance of blood-stage parasites during the
acute phase of infection in CPS immunized mice, recrudescent parasitemia could still be observed in
the chronic phase of infection after challenge, suggesting a parasite variant escapes the protective
immune response (McLean et al., 1982). There are very few reports on protective efficacy of
CPS immunization (or indeed any sporozoite-based vaccine) against direct blood-challenge
(Belnoue et al., 2004; Inoue et al., 2012; Peng et al., 2014). Doll et al. (2014) reported that
sustained, subpatent blood-stage infection after treatment with a commonly used dose of
chloroquine can induce partial blood-stage protection. Low-grade transient blood-stage parasitemia,
achieved by attenuation of blood-stage parasites using an antimalarial drug (Pombo et al., 2002;
Figure 6. Extended blood-stage parasitemia elicits pre-
erythrocytic immunity. Mice received a first infection
with P. chabaudi AS either by mosquito bite (Bite) or
intraperitoneal (ip) injection of 10,000 parasitized eryth-
rocytes obtained from a donor mouse infected by
mosquito bite (Blood (MT)). Blood-stage parasitemia
was self-cured before challenge (C; 98 days post-
infection) using P. chabaudi AS-infected mosquito bites.
Liver parasite burden was determined 42 hr after
mosquito bite challenge as copy number of P. chabaudi-
specific 18S rRNA. Data are displayed relative to the
mean of corresponding liver parasite burden of naive
infection controls (−). Pooled data from two indepen-
dent experiments (Naive (−) and Bite n = 30, Blood
(MT) n = 20) are presented as mean ± SEM, Kruskal
Wallis with Dunn’s multiple comparisons test *p ≤ 0.05,
***p ≤ 0.001.
DOI: 10.7554/eLife.05165.009
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Elliott et al., 2005), a DNA alkylating agent (Good et al., 2013) or genetic tools (Ting et al., 2008;
Aly et al., 2010) similarly provides protection against homologous and heterologous blood-stage
challenge.
We could show that CPS-induced blood-stage immunity is effective against heterologous mosquito
bite challenge with a more virulent and genetically distinct strain of P. chabaudi (Mackinnon and
Read, 1999; Lamb and Langhorne, 2008). In agreement with the observed cross-species protection
after CPS immunization with mefloquine (Inoue et al., 2012), and one study using chemically
attenuated sporozoites for immunization (Purcell et al., 2008), heterologous protection is less
effective than homologous immunity. Nevertheless, CPS immunization can elicit long-lived protection
against both homologous and heterologous blood-stage parasites, which will be important to
minimize disease severity in the case of breakthrough blood-stage infections. This is essential for the
development of an effective multi-stage malaria vaccine (Ellis et al., 2010; Bejon et al., 2011).
In stark contrast to the observed heterologous blood-stage protection after mosquito bite
challenge infection, protection was almost completely abrogated following direct blood-challenge
with virulent parasites obtained after continuous serial blood passage. This suggests that blood-stage
parasites immediately after mosquito transmission express antigens not present on serially blood
passaged parasites and that these antigens may be the target of protective immunity following CPS
immunization. Serially blood passaged parasites can hence escape from CPS-induced blood-stage
immunity. One group of Plasmodium genes, whose expression is altered by mosquito transmission
during blood-stage infection is the Plasmodium interspersed repeat gene family (pir); termed cir in
P. chabaudi (Lawton et al., 2012). Transcription of more than half of all cir genes is increased in
blood-stage parasites after mosquito transmission compared with their transcription after serial blood
passage. This diversification of cir transcription is associated with a more effective host immune
response, which in turn attenuates parasite virulence (Spence et al., 2013). The cir genes could also
be candidate targets for cross-stage immunity, as P. berghei pir genes are also transcribed during the
liver stages (personal communication BM Franke-Fayard and CJ Janse, Leiden University Medical
Center, The Netherlands). An investigation into shared PIR proteins between liver and blood-stage
parasites may hence provide valuable information for multi-stage malaria vaccine development.
Furthermore, the absence of blood-stage protection in previous CPS models may have been due to
challenge with serially blood passaged rather then recently mosquito transmitted blood-stage
parasites. It is therefore always essential to evaluate blood-stage immunity in the context of mosquito
transmission.
As shared antigenic targets between liver- and blood-stage parasites have been described (Tarun
et al., 2008), the exciting possibility of cross-stage protection has been considered but only rarely
assessed. Genetically modified fabb/f- sporozoites that arrest late in liver-stage development protect
against iv challenge with 100 blood-stage parasites (Butler et al., 2011). On the other hand, a blood-
stage infection with serially blood passaged P. yoelii, drug-treated with chloroquine after 4–5 days,
reduces liver parasite load upon iv challenge with 35,000 sporozoites (Belnoue et al., 2008). In our
model of CPS immunization by mosquito bite, it is likely that repeated transient blood-stage infection
during immunization elicits the observed blood-stage protection, although we cannot yet exclude that
responses acquired against pre-erythrocytic antigens, which are shared with blood-stage parasites
(Tarun et al., 2008), contribute as well. Because of the low number of infected hepatocytes after CPS
immunization with P. chabaudi-infected mosquito bites this seems however unlikely. Nevertheless, we
demonstrate unequivocally that extended exposure to blood-stage parasites is an effective
Table 1. Relationship between the dose of immunizing pre-erythrocytic and blood-stage parasites and the acquisition of immunity.
Low dose High dose
Sporozoites (liver-stage parasites) Mosquito bite or 100 sporozoites iv: no
pre-erythrocytic immunity (Figure 3A/B)
10,000 sporozoites iv: pre-erythrocytic
immunity (Figure 3B)
Blood-stage parasites Blood-stage infection curtailed by
chloroquine: partial blood-stage
immunity (Figure 4)
Fulminant, self-cured blood-stage
infection: blood-stage immunity (Spence
et al., 2013); pre-erythrocytic immunity
(Figure 6)
DOI: 10.7554/eLife.05165.010
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stimulator of pre-erythrocytic immunity. Exposure to blood-stage parasites during CPS immunization
may thus significantly contribute to the observed pre-erythrocytic protection in human volunteers
(Roestenberg et al., 2009; Bijker et al., 2013, 2014). Indeed, cross-stage immunity could be
responsible for the unprecedented efficacy of CPS immunization compared to immunization with
irradiated sporozoites (Clyde et al., 1973; Seder et al., 2013), which arrest early during liver-stage
development and never establish a blood-stage infection. While extending exposure to replicating
blood-stage parasites by delayed drug administration is not possible in humans, the incorporation of
chemically (Good et al., 2013) or genetically (Ting et al., 2008; Aly et al., 2010) attenuated
blood-stage parasites should be considered to further enhance the generation and maintenance of
both pre-erythrocytic and blood-stage immunity. This makes CPS immunization a powerful tool for the
development of an effective multi-stage malaria vaccine.
Materials and methods
Mice
Inbred C57BL/6 mice, originally obtained from Jackson Laboratories (Bar Harbor, USA), were bred
under specific pathogen-free conditions at the MRC National Institute for Medical Research (NIMR)
for over 30 years. All experiments were performed in accordance with UK Home Office regulations
(PPL 80/2358) and approved by the ethical review panel at the MRC NIMR. Mice were housed under
reverse light conditions (light 19.00–07.00, dark 07.00–19.00 GMT) at 20–22˚C and 50% relative
humidity, with continuous access to mouse breeder diet and water.
Parasites and mosquitoes
Plasmodium chabaudi chabaudi (P. chabaudi) AS and CB were cloned at the University of Edinburgh
and sent to the NIMR in 1978 and 1982, respectively. Both parasite lines were routinely serially blood-
passaged (SBP) through mice between 26 and 32 times by ip injection of parasitized erythrocytes or
mosquito transmitted according to a recently published protocol (Spence et al., 2012). In brief
C57BL/6 mice were injected ip with 100,000 parasitized erythrocytes and 14 days post infection
gametocytemia was assessed on Giemsa-stained (VWR, Lutterworth, UK) thin blood film. A. stephensi
mosquitoes, pre-treated with 50 μg/ml gentamicin (Sigma, Gillingham, UK) and starved for 24 hr
before transmission, were fed on anaesthetised mice with >0.1% gametocytes of total erythrocytes at
a ratio of >1 mouse per 100 mosquitoes. Mosquitoes were kept at 26.0˚C (± 0.5˚C) in an ultrasonic
humidity cabinet and provided with 8% Fructose and 0.05% 4-Aminobenzoic acid (both Sigma,
Gillingham, UK) feeding solution. After 8 days, a sample of 20 mosquitoes were dissected to assess
development of P. chabaudi oocyts in the midgut. For infection of experimental mice 20–23
mosquitoes were transferred into 25 cl paper cups after 14 days, starved for 24 hr and fed on
anaesthetized mice for 20–25 min at room temperature. Typically, mice were exposed to 9.15 (median,
range 6.9–13.6) P. chabaudi-infected mosquito bites (Spence et al., 2012).
Isolation of sporozoites
Sporozoites were isolated from P. chabaudi-infected mosquito salivary glands 15 or 16 days post
gametocyte feed. Salivary glands were dissected under a stereomicroscope, transferred to a glass
homogenizer and kept in RPMI supplemented with 0.2% Glucose, 0.2% Sodium bicarbonate (both Sigma,
Gillingham, UK), 2 mM L-Glutamine (Gibco, Paisley, UK) and 10% fetal bovine serum (GE Healthcare Life
Sciences, Pittsburgh, Pennsylvania), on ice for maximum 2 hr. Sporozoites were released from the glands
by gentle homogenization and washed three times before enumeration. The number of sporozoites per
infected mosquito was enumerated for each mosquito transmission experiment. For iv injection
P. chabaudi CB sporozoites were used, since mosquitoes infected with this parasite strain harbor an
increased number of sporozoites per infected mosquito in their salivary glands (median 1638, range
175–2576) compared to P. chabaudi AS (median 438, range 43–956) (Spence et al., 2012).
Attenuation of sporozoites by irradiation
To arrest parasite development in the early stages of liver development P. chabaudi CB infected
A. stephensi were exposed to 16 Gray (=16,000 rad) (Nganou-Makamdop et al., 2012b) of
Caesium-137 γ-irradiation 15 or 16 days post gametocyte feed just prior to sporozoite dissection.
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Chemoprophylaxis and sporozoite (CPS) immunization and challenge
regimen
Female age-matched 8–10 week old C57BL/6 mice were infected three times in 2-week intervals with
P. chabaudi: either by P. chabaudi AS-infected mosquito bites or iv injection of P. chabaudi CB
sporozoites. Mice were treated after each immunization with 100 mg/kg chloroquine diphosphate salt
(chloroquine, Sigma, Gillingham, UK) by gavage daily for 10 days, starting from the day of mosquito
transmission. Mock immunized mice received uninfected mosquito bites and chloroquine treatment.
100 days after the last CPS immunization mice were challenged with P. chabaudi AS or P. chabaudi
CB-infected mosquito bites, or via ip injection of 100,000 parasitized erythrocytes (direct blood-
challenge) that were obtained from either a donor mouse infected by mosquito bite or after serial
blood passage. Since each erythrocytic cycle of P. chabaudi is approximately 24 hr long (Stephens
et al., 2012) development of blood-stage parasitemia was monitored daily by microscopy of Giemsa-
stained thin blood films, from erythrocytic cycle 3 to 14 and every other day thereafter. The limit of
detection was 0.01% parasitemia, which equals 1 parasitized red blood cell in 10,000 erythrocytes or
1,000,000 parasitized erythrocytes per ml of blood.
Quantification of liver- and blood-stage parasitemia by quantitative Real
Time PCR
Liver and blood-parasitemia was assessed by quantifying 18S rRNA using qRT PCR. 42 hr after
mosquito bite challenge mice were terminally anaesthetized and immediately upon cessation of
respiration their livers were perfused with 5 ml RNAse-free Phosphate buffered saline (PBS, Gibco,
Paisley, UK). Using the Gentle MACS homogenizer (Miltenyi, Bisley, UK) the whole liver was
homogenized in 4 ml Guanidinium thiocyanate (Sigma, Gillingham, UK) solution (Chomczynski and
Sacchi, 2006), and 600 μl aliquots were stored at −80˚C. To assess blood-parasite burden during CPS
immunization and in the first erythrocytic cycles following bite challenge 10 μl of blood were isolated
from the tip of the mouse-tail and after two washes in RNAse-free PBS stored at −80˚C in 100 μl
Guanidinium thiocyanate solution (Chomczynski and Sacchi, 2006). The first sample was taken either
just before (erythrocytic cycle 0) or 20 hr after liver merozoite egress (erythrocytic cycle 1) and then
every 24 hr for 4 days. Since P. chabaudi displays a synchronous infection (Stephens et al., 2012) all
blood-stage parasites analyzed were therefore at the late trophozoite stage of development. RNA
was extracted from liver- as well as blood-samples using the Guanidinium-thiocyanate-phenol-chlorophorm
method (all Sigma, Gillingham, UK; Chomczynski and Sacchi, 2006). RNA was thereafter reverse
transcribed by PCR (temperature profile: 25˚C for 10 min, 42˚C for 20 min, 98˚C for 5 min) using 75U
MuLV Reverse Transcriptase, 30U RNAse Inhibitor, and 2.5 μM Random Hexamer primers (all Applied
Biosystems, Paisley, UK) per sample. The amount of 18S rRNA copies was quantified by Real-Time
PCR using TaqMan Universal PCR Master Mix (Applied Biosystems, Paisley, UK), 300 ηM forward
primer (5′-AAGCATTAAATAAAGCGAATACATCCTTAT-3′), 300 ηM reverse primer (5′-GGGAGT
TTGGTTTTGACGTTTATGCG-3′), and 50 ηM probe ([6FAM]CAATTGGTTTACCTTTTGCTCTTT[TAM]).
All reactions were performed in the ABI 7900 HT Real Time PCR machine (temperature profile: 50˚C
for 2 min, 95˚C for 10 min, 40 cycles of 95˚C for 15 s and 60˚C for 1 min). The amount of parasite 18S
rRNA in the liver was calculated based on a Standard curve of known copy numbers of 18S rRNA. For
every experiment liver-parasite burden was normalized to the mean burden of controls infected in the
same experiment. Blood-stage parasitemia was quantified based on a Standard curve of 10-fold
dilutions of mosquito transmitted P. chabaudi AS late trophozoites prepared identically to the
samples.
Statistical analysis
Data were analyzed using GraphPad Prism v7. Unpaired data between two groups at a specific time
point were analyzed by Mann–Whitney test (two-tailed, non-parametric). Differences between more
than two groups were analyzed by non-parametric Kruskal–Wallis test with Dunn’s multiple comparisons
test. Significant differences are indicated by asterisks with *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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